Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02309554 · ClinicalTrials.gov registry record · Phase 1
Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel
A Phase 1 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02309554 is a Phase 1 study that has completed, run by CONRAD. The registered enrollment target is 27 participants.
The verdict
NCT02309554, a Phase 1 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This post coital test study is a Phase I multi-center, randomized, crossover, non-significant risk device study to be carried out at two clinical sites/centers. The products to be tested are the SILCS diaphragm with 3% Nonoxynol-9 Gel (N-9) (spermicide), the SILCS diaphragm with ContraGel, and the SILCS diaphragm alone. Participants will be randomized to the order of product use, with a goal of 10 participants completing the study.
Interventions
- OTHER SILCS diaphragm used with ContraGel
- OTHER SILCS diaphragm used with 3% Nonoxynol-9
- OTHER SILCS diaphragm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02309554
The ClinicalTrials.gov registry entry for NCT02309554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SILCS diaphragm used with ContraGel is the first listed.
NCT02309554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02309554 about?
NCT02309554 is a clinical study titled "Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel". This post coital test study is a Phase I multi-center, randomized, crossover, non-significant risk device study to be carried out at two clinical sites/centers. The products to be tested are the SILCS diaphragm with 3% Nonoxynol-9 Gel (N-9) (spermicide), the SILCS diaphragm with ContraGel, and the S...
What is the current status of trial NCT02309554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2014-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02309554?
The interventions under investigation include: SILCS diaphragm used with ContraGel (OTHER), SILCS diaphragm used with 3% Nonoxynol-9 (OTHER), SILCS diaphragm (OTHER).
Who is sponsoring clinical trial NCT02309554?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.